Peptron, Inc. and Qilu Pharmaceutical announced that the companies have entered into an exclusive licensing agreement for the manufacturing, development and commercialization of Peptron's PAb001-ADC, the antibody-drug conjugate (the "ADC") product containing the anti-MUC1 monoclonal antibody PAb001 as effective of March 26, 2021. Under the terms of the agreement, Peptron grants Qilu an exclusive global right and license to develop, manufacture, sell, and commercialize PAb001-ADC for the treatment of cancers.